Malaria and Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030)

Malaria and Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Send Enquiry
Item ID: TIPRE00030125 Category: Tags: , ,

$3,185$5,985

Description

The malaria and sickle cell disease treatment market is expected to grow from US$ 4.457 billion in 2022 to US$ 29.179 billion by 2030; it is estimated to grow at a CAGR of 26.5% from 2022 to 2030. The market for malaria and sickle cell disease treatment is growing due to the increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, factors such as a counterfeit antimalarial drug and subsequent drug resistance are restraining the market growth.

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial and SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria and sickle cell disease. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial and SCD drugs/vaccines that are under clinical development are mentioned in the table below:

Table 1. Malaria Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Artefenomel Sanofi Phase IIb

KAE609 Novartis AG Phase IIb

KAF156 Novartis AG Phase IIb

DSM265 Takeda Pharmaceutical Company Phase IIa

SANARIA PfSPZ-GA1 Sanaria Phase II

SANARIA PfSPZ Vaccine – Radiation Attenuated PfSPZ Vaccine Sanaria Phase II

SANARIA PfSPZ-CVac Sanaria Phase II

MSP3-CRM-Vac4All Vac4All Phase I

Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa

Source: Company Website,the research team Analysis

?

Table 2. Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Inclacumab Pfizer Phase III

Voxelotor Pfizer Phase III

GBT021601 Pfizer Phase II

PF-07209326 Pfizer Phase II

RG6107 Roche Phase II

GSK4172239D GSK Phase I

BEAM¬–101 Beam Therapeutics Phase I/II

HGB-206 Bluebird Bio, Inc. Phase I/II

HGB-210 Bluebird Bio, Inc. Phase III

ALXN1820 Alexion Phase II

NCT05714969 Takeda Pharmaceutical Company Limited Phase 2b

NCT03997760 Takeda Pharmaceutical Company Limited Phase I

Source: Company Website,the research team Analysis

Therefore, the growing number of antimalarial and SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

The report segments the malaria and sickle cell disease treatment market as follows:

The malaria and sickle cell disease (SCD) treatment market is segmented on the basis of treatment, route of administration, distribution channel, and geography. Based on treatment, the market is divided into malaria and sickle cell disease. In terms of route of administration, the malaria and sickle cell disease (SCD) treatment market is divided into oral and parenteral. Based on distribution channel, the market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the malaria and sickle cell disease treatment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Route of Administration-Based Insights

By route of administration, the malaria treatment market is bifurcated into oral and parenteral. In 2022, the oral segment held a larger market share, and the parenteral segment is estimated to record a faster CAGR during 2020–2030. Oral drug delivery is the most ideal and suitable route of drug administration as it offers high patient compliance, non-invasiveness, least sterility constraints, cost-effectiveness, flexibility in the design of dosage form, and ease in the manufacturing process. Benefits such as ease of administration and long-term cost efficiency are the major factors fueling the adoption of oral drugs.

Distribution Channel-Based Insights

Based on distribution channel, the malaria and sickle cell disease (SCD) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. A tender is an offer to do specific duties or provide items for a fixed amount. In the first step of a tender procedure, contractors will be asked to submit sealed bids for construction or to offer particularly planned services or products within a specific time limit. The e-tendering procedure in India is designed to ensure that work for the government or a specific client is completed in a timely manner.

A few of the major primary and secondary sources referred to while preparing the report on the malaria and sickle cell disease treatment market are the World Health Organization (WHO), the US Census Bureau, and CDC, among others.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Government and Private Sector’s Initiatives to Raise Awareness About SCD to Drive Global Sickle Cell Disease Treatment Market During 2022–2030

According to our latest study on ” Malaria and Sickle Cell Disease Treatment Market Forecast to 2030 – Global Analysis –Treatment, Route of Administration, and Distribution Channel,” the market is expected to grow from US$ 4.691 billion in 2022 to US$ 29.179 billion by 2030; it is estimated to grow at a CAGR of 26.5% during 2022–2030. The market growth is primarily attributed to increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, lack of sickle cell disease treatment options and the availability of counterfeit antimalarial drugs, followed by subsequent drug resistance are hindering the market growth.

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial and SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria and sickle cell disease. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial and SCD drugs/vaccines that are under clinical development are mentioned in the table below:

Table 1. Malaria Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Artefenomel Sanofi Phase IIb

KAE609 Novartis AG Phase IIb

KAF156 Novartis AG Phase IIb

DSM265 Takeda Pharmaceutical Company Phase IIa

SANARIA PfSPZ-GA1 Sanaria Phase II

SANARIA PfSPZ Vaccine – Radiation Attenuated PfSPZ Vaccine Sanaria Phase II

SANARIA PfSPZ-CVac Sanaria Phase II

MSP3-CRM-Vac4All Vac4All Phase I

Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa

Source: Company Website,the research team Analysis

?

Table 2. Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Inclacumab Pfizer Phase III

Voxelotor Pfizer Phase III

GBT021601 Pfizer Phase II

PF-07209326 Pfizer Phase II

RG6107 Roche Phase II

GSK4172239D GSK Phase I

BEAM¬–101 Beam Therapeutics Phase I/II

HGB-206 Bluebird Bio, Inc. Phase I/II

HGB-210 Bluebird Bio, Inc. Phase III

ALXN1820 Alexion Phase II

NCT05714969 Takeda Pharmaceutical Company Limited Phase 2b

NCT03997760 Takeda Pharmaceutical Company Limited Phase I

Source: Company Website,the research team Analysis

Therefore, the growing number of antimalarial and SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Increasing Prevalence of Malaria and Sickle Cell Disease to Bolster Malaria and Sickle Cell Disease Treatment Market Growth

Malaria, one of the acute febrile illnesses, is caused by plasmodium parasites and spreads through the infected female Anopheles mosquitoes. Five parasite species in humans mainly cause malaria, and two of these species—Plasmodium falciparum and P. vivax—are considered the greatest threat to human health. Also, P. falciparum is the deadliest malarial parasite, and it is most widely spread across the African continent. Further, P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa. According to the latest World Malaria Report (WMR) 2020 from the World Health Organization (WHO), 241 million cases of malaria were reported in the world, in comparison to 227 million cases that were logged in 2019. According to the same source, the number of deaths caused due to malaria has an annual rise of 69,000 deaths. Approximately two-thirds of these deaths, i.e., 47,000, were caused by disruptions in healthcare services during the COVID-19 outbreak; the remaining one-third of deaths, i.e., 22,000 reflected a recent change in the WHO’s methodology for calculating malaria mortality (irrespective of COVID-19 disruptions).

?

The WHO African region accounted for a high share of the global burden of malaria. In 2020, ~95% of global cases and ~96% of deaths were reported in Africa due to malaria, and ~80% of the total deaths that were reported were in children aged 5 and below. According to the WHO, four African countries, Nigeria, Tanzania, the Democratic Republic of the Congo, and Mozambique, recorded approximately half of all malaria-related deaths that were reported globally. According to the LANCET Regional Health 2020, African countries had the highest burden of malaria; P. falciparum is a notable cause of the highest mortality rates in children younger than 5, which accounts for ?77% across the world; in African countries, P. falciparum accounts for ?96% of total mortalities caused among children by malaria. P. vivax has been a causal agent of 2% (4.5 million) of the total cases of malaria, mainly from Asia. According to WMR 2021, ?2% of the global burden of malaria was recorded by Southeast Asian countries, where India accounted for 83% of estimated malaria cases and 82% of deaths associate with malaria in 2020.

The treatment plan for sickle cell disease (SCD) can be divided into two categories: maintaining health and treating complications. Sickle cell anemia has genotypic and phenotypic variants that are based on unique mutations in hemoglobin genes. There is a high prevalence of the disease as well as a rise in its severity across the globe. According to the WHO, approximately 5% of the world’s population has genes inhibiting hemoglobin diseases such as sickle cell anemia and thalassemia. According to a study on sickle cell disease published in the National Library of Medicine, more than 300,000 babies are born with severe hemoglobin disorders each year; also, 400,000 newborns are expected to have sickle cell disease by 2050. In addition, according to a published report in 2023 by the American Society of Hematology, the estimated number of people suffering from SCD in the US is approximately 70,000–100,000. Thus, the rising prevalence of malaria and sickle cell disease in different regions across the globe boosts the malaria and sickle cell disease treatment market growth.

Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are among the leading companies operating in the malaria and sickle cell disease treatment market.

Malaria and Sickle Cell Disease Treatment Market, by Region, 2022 (%)

Source:the research team Analysis

Based on treatment, the sickle cell disease treatment market is segmented into malaria and sickle cell disease (SCD). Based on route of administration, the sickle cell disease treatment market is bifurcated into oral and parenteral. Based on distribution channel, the sickle cell disease treatment market is divided into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the sickle cell disease treatment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, Nigeria, Congo, Tanzania, Uganda, Ghana, Kenya, Zambia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South & Central America PEST Analysis
5. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Burden of Periodontal Diseases and Oral Cancer
5.1.2 Strategic Developments by Market Players
5.2 Market Restraints
5.2.1 High Cost of Products & Procedures and Delays in Dental Check-ups
5.3 Market Opportunities
5.3.1 Technological Developments in Dentistry
5.4 Future Trends
5.4.1 Digitization of Dentistry with CAD/CAM Technology
5.5 Impact Analysis:
6. Dental Bone Graft Substitute and Barrier Membrane Market – South & Central America Market Analysis
6.1 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Revenue (US$ Mn), 2022 – 2030
7. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by Product
7.1 Overview
7.2 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by Product 2022 & 2030 (%)
7.3 Dental Bone Graft Substitute
7.3.1 Overview
7.3.2 Dental Bone Graft Substitute: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.3 Allograft
7.3.3.1 Overview
7.3.3.2 Allograft: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.4 Xenograft
7.3.4.1 Overview
7.3.4.2 Xenograft: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.5 Synthetic Bone Graft
7.3.5.1 Overview
7.3.5.2 Synthetic Bone Graft: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.6 Autografts
7.3.6.1 Overview
7.3.6.2 Autografts: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.7 Alloplasts
7.3.7.1 Overview
7.3.7.2 Alloplasts: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.8 Demineralized Bone Matrix (DBM)- Allograft
7.3.8.1 Overview
7.3.8.2 Demineralized Bone Matrix (DBM)- Allograft: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.3.9 Others
7.3.9.1 Overview
7.3.9.2 Others: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Dental Barrier Membrane
7.4.1 Overview
7.4.2 Dental Barrier Membrane: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4.3 Resorbable Membrane
7.4.3.1 Overview
7.4.3.2 Resorbable Membrane: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
7.4.4 Non-Resorbable Membrane
7.4.4.1 Overview
7.4.4.2 Non-Resorbable Membrane: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by Procedures
8.1 Overview
8.2 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by Procedures 2022 & 2030 (%)
8.3 Guided Bone Regeneration Procedures (GBR)
8.3.1 Overview
8.3.2 Guided Bone Regeneration Procedures (GBR): South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Guided Tissue Regeneration Procedures (GTR)
8.4.1 Overview
8.4.2 Guided Tissue Regeneration Procedures (GTR): South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Sinus-lift Procedures and Ridge-split Procedures
8.5.1 Overview
8.5.2 Sinus-lift Procedures and Ridge-split Procedures: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Alveolar Ridge Preservation (ARP)
8.6.1 Overview
8.6.2 Alveolar Ridge Preservation (ARP): South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Block-graft Procedures
8.7.1 Overview
8.7.2 Block-graft Procedures: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Periodontal Regeneration Procedures
8.8.1 Overview
8.8.2 Periodontal Regeneration Procedures: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Socket Preservation
8.9.1 Overview
8.9.2 Socket Preservation: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
8.10 Others
8.10.1 Overview
8.10.2 Others: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Dental Clinics
9.4.1 Overview
9.4.2 Dental Clinics: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market – Country Analysis
10.1 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, Revenue And Forecast to 2030
10.1.1 Overview
10.1.1.1 South & Central America Dental Bone Graft Substitute and Barrier Membrane Market by Country
10.1.1.2 Brazil
10.1.1.2.1 Overview
10.1.1.2.2 Brazil Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.2.1 Brazil Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.2.2.2 Brazil Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.2.3 Brazil Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.2.4 Brazil Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.2.5 Brazil Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.3 Argentina
10.1.1.3.1 Overview
10.1.1.3.2 Argentina Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.3 Argentina Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.3.3.1 Argentina Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.3.3.2 Argentina Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.3.4 Argentina Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.3.5 Argentina Dental Bone Graft Substitute and Barrier Membrane Market, by End User
10.1.1.4 Rest of South & Central America
10.1.1.4.1 Overview
10.1.1.4.2 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.3 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, by Product
10.1.1.4.3.1 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Bone Graft Substitute
10.1.1.4.3.2 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, by Dental Barrier Membrane
10.1.1.4.4 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, by Procedures
10.1.1.4.5 Rest of South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, by End User
11. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market Industry Landscape
11.1 Overview
11.2 Growth Strategies in South & Central America Dental Bone Graft Substitute and Barrier Membrane Market
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. South & Central America Dental Bone Graft Substitute and Barrier Membrane Market, Key Company Profiles
12.1 Geistlich Pharma AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Medtronic Plc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Dentsply Sirona Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ZimVie Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Regenity Biosciences Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Institut Straumann AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF FIGURES

Figure 1. PEST Analysis – Malaria
Figure 2. PEST Analysis – Sickle Cell Disease Treatment
Figure 3. Malaria and Sickle Cell Disease Treatment Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Malaria Treatment Market Revenue (US$ million), 2020 – 2030
Figure 6. Sickle Cell Disease Treatment Market Revenue (US$ million), 2020 – 2030
Figure 7. Malaria: Geography Analysis Market Revenue (US$ million), 2022 – 2030
Figure 8. Sickle Cell Disease: Geography Analysis Market Revenue (US$ million), 2022 – 2030
Figure 9. Malaria Treatment Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 10. Sickle Cell Disease Treatment Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 11. Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Malaria Treatment Market Revenue Share, by Route of Administration 2022 & 2030 (%)
Figure 14. Sickle Cell Disease Market Revenue Share, by Route of Administration 2022 & 2030 (%)
Figure 15. Oral: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Oral: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Parenteral: Malaria and Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Malaria Treatment Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 20. Sickle Cell Disease Treatment Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 21. Direct Tender: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Direct Tender: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Hospital Pharmacies: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Hospital Pharmacies: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Retail Pharmacies: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Online Pharmacies: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Online Pharmacies: Malaria Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Others: Sickle Cell Disease Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. North America Malaria Treatment Market, By Geography, 2022 ($Mn)
Figure 32. North America Sickle Cell Disease Treatment Market, By Geography, 2022 ($Mn)
Figure 33. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. North America: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 36. North America: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 37. US: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. US: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. Canada: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Canada: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. Mexico: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Mexico: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Europe Malaria Treatment Market, By Geography, 2022 ($Mn)
Figure 44. Europe Malaria and Sickle Cell Disease Treatment Market, By Geography, 2022 ($Mn)
Figure 45. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Europe: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 48. Europe: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 49. France: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. France: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. UK: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 52. UK: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Italy: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 54. Italy: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Germany: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. Germany: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. Spain: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. Spain: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 59. Rest of Europe: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. Rest of Europe: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 61. Malaria Treatment Market, 2022 ($Mn)
Figure 62. Sickle Cell Disease Treatment Market, 2022 ($Mn)
Figure 63. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 65. Asia Pacific: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 66. Asia Pacific: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 67. China: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 68. Japan: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 69. Japan: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 70. India: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 71. India: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 72. South Korea: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 73. South Korea: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 74. Australia: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 75. Australia: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 76. Rest of Asia Pacific: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 77. Rest of Asia Pacific: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 78. Malaria Treatment Market, 2022 (US$ Mn)
Figure 79. Sickle Cell Disease Treatment Market, 2022 (US$ Mn)
Figure 80. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 81. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 82. Middle East & Africa: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 83. Middle East & Africa: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 84. Saudi Arabia: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 85. Saudi Arabia: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 86. UAE: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 87. UAE: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 88. South Africa: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 89. South Africa: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 90. Kenya: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 91. Kenya: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 92. Tanzania: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 93. Tanzania: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 94. Rwanda: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 95. Rwanda: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 96. Nigeria: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 97. Nigeria: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 98. Ghana: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 99. Ghana: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 100. Uganda: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 101. Uganda: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 102. Angola: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 103. Angola: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 104. Cameroon: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 105. Cameroon: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 106. Senegal: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 107. Senegal: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 108. Zambia: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 109. Zambia: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 110. Rest of Middle East & Africa: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 111. Rest of Middle East & Africa: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 112. Malaria Treatment Market, 2022 ($Mn)
Figure 113. Sickle Cell Disease Treatment Market, 2022 ($Mn)
Figure 114. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 115. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 116. Asia Pacific: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 117. Asia Pacific: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 118. China: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 119. Japan: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 120. Japan: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 121. India: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 122. India: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 123. South Korea: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 124. South Korea: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 125. Australia: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 126. Australia: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 127. Rest of Asia Pacific: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 128. Rest of Asia Pacific: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 129. Malaria Treatment Market, 2022 ($Mn)
Figure 130. Sickle Cell Disease Treatment Market, 2022 ($Mn)
Figure 131. Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 132. Sickle Cell Disease Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 133. South & Central America: Malaria Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 134. South & Central America: Sickle Cell Disease Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 135. Brazil: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 136. Brazil: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 137. Argentina: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 138. Rest of South & Central America: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 139. Rest of South & Central America: Sickle Cell Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 140. Growth Strategies in the Malaria and Sickle Cell Disease Treatment Market

The List of Companies – Malaria and Sickle Cell Disease Treatment Market
– Cipla Ltd
– Pfizer Inc
– Sun Pharmaceutical Industries Ltd
– Sanofi SA
– GSK Plc
– Novartis AG
– Pfizer Inc
– Emmaus Life Sciences Inc
– AdvaCare Pharma USA LLC
– VLP Therapeutics LLC
–  Lupin Ltd
–  

Reviews

There are no reviews yet.

Be the first to review “Malaria and Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030)”